Acutely decompensated congestive heart failure: new therapies for an old problem

References

• Centers for Disease Control and Prevention. Changes in mortality from heart failure – United States, 1980–1995. JAMA. 280(10), 874–875 (1998).
   PubMed Web of Science ®Google Scholar
• Hunt SA, Baker DW, Chin MH et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J. Am. Coll. Cardiol. 38(7), 2101–2113 (2001).
   PubMed Web of Science ®Google Scholar
• Masoudi FA, Havranek EP, Krumholz HM. The burden of chronic congestive heart failure in older persons: magnitude and implications for policy and research. Heart Fail. Rev. 1, 9–16 (2002).
   Google Scholar
• O’Connell JB. The economic burden of heart failure. Clin. Cardiol. III(Suppl. 3), 6–10 (2000).
   Google Scholar
• McCullough PA, Philbin EF, Spertus JA et al. Confirmation of a heart failure epidemic: findings from the Resource Utilization Among Congestive Heart Failure (REACH) study. J. Am. Coll. Cardiol. 39(1), 60–69 (2002).
   PubMed Web of Science ®Google Scholar
• Johansen H, Strauss B, Arnold JM et al. On the rise: The current and projected future burden of congestive heart failure hospitalization in Canada. Can. J. Cardiol. 19(4), 430–435 (2003).
   PubMed Web of Science ®Google Scholar
• Liu P, Arnold M, Belenkie I et al. The 2001 Canadian Cardiovascular Society consensus guideline update for the management and prevention of heart failure. Can. J. Cardiol. (Suppl. E), 5E–25E (2001).
   Google Scholar
• Hunt SA, Baker DW, Chin MH et al. ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure): Developed in Collaboration With the International Society for Heart and Lung Transplantation; Endorsed by the Heart Failure Society of America. Circulation 104(24), 2996–3007 (2001).
   PubMed Web of Science ®Google Scholar
• Smith GL, Masoudi FA, Vaccarino V et al. Outcomes in heart failure patients with preserved ejection fraction: mortality, readmission, and functional decline. J. Am. Coll. Cardiol. 41(9), 1510–1518 (2003).
   PubMed Web of Science ®Google Scholar
• Klapholz M, Maurer M, Lowe AM et al. Hospitalization for heart failure in the presence of a normal left ventricular ejection fraction: results of the New York Heart Failure Registry. J. Am. Coll. Cardiol. 43(8), 1432–1438 (2004).
   PubMed Web of Science ®Google Scholar
• Yusuf S, Pfeffer MA, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 362(9386), 777–781 (2003).
   PubMed Web of Science ®Google Scholar
• Colucci WS. Pathophysiology of heart failure. In: Heart Disease: A textbook of cardiovascular medicine. Brausnwald E (Ed.). WB Saunders, PA, USA, 394–420 (1997).
   Google Scholar
• Fonarow GC. The Acute Decompensated Heart Failure National Registry (ADHERE): opportunities to improve care of patients hospitalized with acute decompensated heart failure. Rev. Cardiovasc. Med. 4(Suppl. 7), S21–S30 (2003).
   PubMedGoogle Scholar
• Gillespie ND, McNeill G, Pringle T et al. Cross sectional study of contribution of clinical assessment and simple cardiac investigations to diagnosis of left ventricular systolic dysfunction in patients admitted with acute dyspnoea. Br. Med. J. 314(7085), 936–940 (1997).
   PubMedGoogle Scholar
• McKee PA, Castelli WP, McNamara PM et al. The natural history of congestive heart failure: the Framingham study. N. Engl. J. Med. 285(26), 1441–1446 (1971).
   PubMed Web of Science ®Google Scholar
• Remes J, Miettinen H, Reunanen A et al. Validity of clinical diagnosis of heart failure in primary healthcare. Eur. Heart J. 12(11), 1245–1246 (1991).
   PubMedGoogle Scholar
• Wright SP, Doughty RN, Pearl A et al. Plasma amino-terminal pro-brain natriuretic peptide and accuracy of heart-failure diagnosis in primary care: a randomized, controlled trial. J. Am. Coll. Cardiol. Nov 19 42(10), 1793–1800 (2003).
   PubMed Web of Science ®Google Scholar
• Januzzi JL, Camargo CA, Anwaruddin S et al. Emergency evaluation of shortness of breath: the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE). J. Am. Coll. Cardiol. 43, 235(a) (2004).
   Google Scholar
• Forman DE, Butler J, Wang Y et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J. Am. Coll. Cardiol. 43(1), 61–67 (2004).
   PubMed Web of Science ®Google Scholar
• Baker GR, Norton PG, Flintoft V et al. The Canadian Adverse Events Study: the incidence of adverse events among hospital patients in Canada. Can. Med. Assoc. J. 170(11), 1678–1686 (2004).
   PubMed Web of Science ®Google Scholar
• Nakagawa O, Ogawa Y, Itoh H et al. Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy. Evidence for brain natriuretic peptide as an ‘emergency’ cardiac hormone against ventricular overload. J. Clin. Invest. 3, 1280–1287 (1995).
   Google Scholar
• Raymond I, Groenning BA, Hildebrandt PR et al. The influence of age, sex and other variables on the plasma level of N-terminal pro brain natriuretic peptide in a large sample of the general population. Heart 89(7), 745–751 (2003).
   Google Scholar
• Maisel AS, Clopton P, Krishnaswamy P et al. Impact of age, race, and sex on the ability of B-type natriuretic peptide to aid in the emergency diagnosis of heart failure: results from the Breathing Not Properly (BNP) multinational study. Am. Heart J. 147(6), 1078–1084 (2004).
   PubMed Web of Science ®Google Scholar
• Cowie MR, Jourdain P, Maisel A et al. Clinical applications of B-type natriuretic peptide (BNP) testing. Eur. Heart J. 24(19), 1710–1718 (2003).
   Google Scholar
• Cowie MR, Struthers AD, Wood DA et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 350(9088), 1349–1353 (1997).
   PubMed Web of Science ®Google Scholar
• Harrison A, Morrison LK, Krishnaswamy P et al. B-type natriuretic peptide predicts future cardiac events in patients presenting to the emergency department with dyspnea. Ann. Emerg. Med. (2), 131–138 (2002).
   Google Scholar
• Omland T. Heart failure in the emergency department: is B-type natriuretic peptide a better prognostic indicator than clinical assessment? J. Am. Coll. Cardiol. 44(6), 1334–1336 (2004).
   PubMedGoogle Scholar
• Omland T, Aakvaag A, Bonarjee VV et al. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. Circulation 93(11), 1963–1969 (1996).
   PubMed Web of Science ®Google Scholar
• Wu AH, Smith A. Biological variation of the natriuretic peptides and their role in monitoring patients with heart failure. Eur. J. Heart Fail. 6(3), 355–358 (2004).
   PubMed Web of Science ®Google Scholar
• James SK, Lindahl B, Siegbahn A et al. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy. Circulation 108(3), 275–281 (2003).
   PubMed Web of Science ®Google Scholar
• Maisel AS, Krishnaswamy P, Nowak RM et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N. Engl. J. Med. 347(3), 161–167 (2002).
   PubMed Web of Science ®Google Scholar
• Mueller C, Scholer A, Laule-Kilian K et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N. Engl. J. Med. 350(7), 647–654 (2004).
   PubMed Web of Science ®Google Scholar
• Januzzi JL Jr, Camargo CA, Anwaruddin S et al. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am. J. Cardiol. 95(8), 948–954 (2005).
   PubMed Web of Science ®Google Scholar
• Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure. Eur. Heart J. (17), 1527–1560 (2001).
   Google Scholar
• Liu P, Arnold JM, Belenkie I et al. The 2002/3 Canadian Cardiovascular Society consensus guideline update for the diagnosis and management of heart failure. Can. J. Cardiol. 19(4), 347–356 (2003).
   PubMedGoogle Scholar
• Logeart D, Thabut G, Jourdain P et al. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. J. Am. Coll. Cardiol. 43(4), 635–641 (2004).
   PubMed Web of Science ®Google Scholar
• Nieminen MS, Bohm M, Cowie MR et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur. Heart J. 26(4), 384–416 (2005).
   PubMed Web of Science ®Google Scholar
• Lee G, DeMaria AN, Amsterdam EA et al. Comparative effects of morphine, meperidine and pentazocine on cardiocirculatory dynamics in patients with acute myocardial infarction. Am. J. Med. 60(7), 949–955 (1976).
   PubMed Web of Science ®Google Scholar
• Bersten AD, Holt AW, Vedig AE et al. Treatment of severe cardiogenic pulmonary edema with continuous positive airway pressure delivered by face mask. N. Engl. J. Med. 325(26), 1825–1830 (1991).
   PubMed Web of Science ®Google Scholar
• Lin M, Yang YF, Chiang HT et al. Reappraisal of continuous positive airway pressure therapy in acute cardiogenic pulmonary edema. Short-term results and long-term follow-up. Chest 107(5), 1379–1386 (1995).
   PubMed Web of Science ®Google Scholar
• Lin M, Chiang HT. The efficacy of early continuous positive airway pressure therapy in patients with acute cardiogenic pulmonary edema. J. Formos. Med. Assoc. 90(8), 736–743 (1991).
   PubMedGoogle Scholar
• Kelly CA, Newby DE, McDonagh TA et al. Randomised controlled trial of continuous positive airway pressure and standard oxygen therapy in acute pulmonary oedema; effects on plasma brain natriuretic peptide concentrations. Eur. Heart J. 23(17), 1379–1386 (2002).
   PubMed Web of Science ®Google Scholar
• Mehta S, Jay GD, Woolard RH et al. Randomized, prospective trial of bilevel versus continuous positive airway pressure in acute pulmonary edema. Crit. Care Med. 25(4), 620–628 (1997).
   PubMed Web of Science ®Google Scholar
• Pang D, Keenan SP, Cook DJ et al. The effect of positive pressure airway support on mortality and the need for intubation in cardiogenic pulmonary edema: a systematic review. Chest 114(4), 1185–1192 (1998).
   PubMed Web of Science ®Google Scholar
• Sharon A, Shpirer I, Kaluski E et al. High-dose intravenous isosorbide-dinitrate is safer and better than Bi-PAP ventilation combined with conventional treatment for severe pulmonary edema. J. Am. Coll. Cardiol. Sep 36(3), 832–837 (2000).
   PubMedGoogle Scholar
• Rabacal C, Ribeiro H, Nuno L et al. The efficacy of isosorbide dinitrate administered in an intravenous bolus in acute cardiogenic pulmonary edema. Rev. Port. Cardiol. 12(12), 1029–1035, 1000 (1993).
   PubMedGoogle Scholar
• Abraham WT, Adams KF, Fonarow GC et al. In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J. Am. Coll. Cardiol. 46(1), 57–64 (2005).
   PubMed Web of Science ®Google Scholar
• Adams KF Jr, Fonarow GC, Emerman CL et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am. Heart J. 149(2), 209–216 (2005).
   PubMed Web of Science ®Google Scholar
• Cotter G, Metzkor E, Kaluski E et al. Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. Lancet. 351(9100), 389–393 (1998).
   PubMed Web of Science ®Google Scholar
• Cohen MV, Kirk ES. Differential response of large and small coronary arteries to nitroglycerin and angiotensin. Autoregulation and tachyphylaxis. Circ. Res. 33(4), 445–453 (1973).
   PubMedGoogle Scholar
• Cotter G, Kaluski E, Stangl K et al. The hemodynamic and neurohormonal effects of low doses of tezosentan (an endothelin A/B receptor antagonist) in patients with acute heart failure. Eur. J. Heart Fail. 6(5), 601–609 (2004).
   PubMed Web of Science ®Google Scholar
• Torre-Amione G, Young JB, Colucci WS et al. Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure. J. Am. Coll. Cardiol. 42(1), 140–147 (2003).
   PubMed Web of Science ®Google Scholar
• Udelson JE, Smith WB, Hendrix GH et al. Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 104(20), 2417–2423 (2001).
   PubMed Web of Science ®Google Scholar
• Cowburn PJ, Cleland JG, McDonagh TA et al. Comparison of selective ET(A) and ET(B) receptor antagonists in patients with chronic heart failure. Eur. J. Heart Fail. (1), 37–42 (2005).
   Google Scholar
• Abraham WT, Lowes BD, Ferguson DA et al. Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. J. Card. Fail. 4(1), 37–44 (1998).
   PubMedGoogle Scholar
• Yoshimura M, Yasue H, Morita E et al. Hemodynamic, renal, and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure. Circulation 84(4), 1581–1588 (1991).
   PubMed Web of Science ®Google Scholar
• Holmes SJ, Espiner EA, Richards AM et al. Renal, endocrine, and hemodynamic effects of human brain natriuretic peptide in normal man. J. Clin. Endocrinol. Metab. 76(1), 91–96 (1993).
   PubMed Web of Science ®Google Scholar
• Saper CB, Kibbe MR, Hurley KM et al. Brain natriuretic peptide-like immunoreactive innervation of the cardiovascular and cerebrovascular systems in the rat. Circ. Res. 67(6), 1345–1354 (1990).
   PubMedGoogle Scholar
• Colucci WS, Elkayam U, Horton DP et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N. Engl. J. Med. 343(4), 246–253 (2000).
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Gattis WA, Adams KF Jr et al. Rationale and design of the pilot randomized study of nesiritide versus dobutamine in heart failure (PRESERVD-HF). Am. Heart J. 145(Suppl. 2), S55–S57 (2003).
   Google Scholar
• Silver MA, Horton DP, Ghali JK et al. Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acutely decompensated heart failure. J. Am. Coll. Cardiol. 39(5), 798–803 (2002).
   PubMed Web of Science ®Google Scholar
• Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 111(12), 1487–1491 (2005).
   PubMed Web of Science ®Google Scholar
• Sackner-Bernstein JD, Kowalski M, Fox M et al. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA 293(15), 1900–1905 (2005).
   PubMed Web of Science ®Google Scholar
• Cuffe MS, Califf RM, Adams KF Jr et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 287(12), 1541–1547 (2002).
   PubMed Web of Science ®Google Scholar
• Follath F, Cleland JG, Just H et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 360(9328), 196–202 (2002).
   PubMed Web of Science ®Google Scholar
• Delle Karth G, Schillinger M, Geppert A et al. Ibutilide for rapid conversion of atrial fibrillation or flutter in a mixed critically ill patient population. Wien. Klin. Wochenschr. 117(3), 92–97 (2005).
   PubMedGoogle Scholar
• Hennersdorf MG, Perings SM, Zuhlke C et al. Conversion of recent-onset atrial fibrillation or flutter with ibutilide after amiodarone has failed. Intensive Care Med. 28(7), 925–929 (2002).
   PubMed Web of Science ®Google Scholar
• Howlett JG, Johnstone DE, Sketris I et al. Identifying opportunities to address the congestive heart failure burden: the Improving Cardiovascular Outcomes in Nova Scotia (ICONS) study. Can. J. Cardiol. 19(4), 439–444 (2003).
   PubMed Web of Science ®Google Scholar
• Carlson JE. High prevalence of questionable medication use in congestive heart failure. Am. J. Med. 101(2), 237–239 (1996).
   PubMedGoogle Scholar
• Fonarow GC, Horwich TB. Prevention of heart failure: effective strategies to combat the growing epidemic. Rev. Cardiovasc. Med. 4(1), 8–17 (2003).
   PubMedGoogle Scholar
• Krumholz HM, Amatruda J, Smith GL et al. Randomized trial of an education and support intervention to prevent readmission of patients with heart failure. J. Am. Coll. Cardiol. 39(1), 83–89 (2002).
   PubMed Web of Science ®Google Scholar
• McAlister FA, Ezekowitz JA, Wiebe N et al. Systematic review: cardiac resynchronization in patients with symptomatic heart failure. Ann. Intern. Med. 141(5), 381–390 (2004).
   PubMed Web of Science ®Google Scholar
• Ghali JK, Kadakia S, Cooper R et al. Precipitating factors leading to decompensation of heart failure. Traits among urban blacks. Arch. Intern. Med. 148(9), 2013–2016 (1988).
   PubMedGoogle Scholar
• Gustafsson F, Arnold JM. Heart failure clinics and out-patient management: review of the evidence and call for quality assurance. Eur. Heart J. 25(18), 1596–1604 (2004).
   PubMed Web of Science ®Google Scholar
• Krumholz HM, Chen YT, Wang Y et al. Predictors of readmission among elderly survivors of admission with heart failure. Am. Heart J. 139(1 Pt. 1), 72–77 (2000).
   PubMed Web of Science ®Google Scholar
• Krumholz HM, Wang Y, Parent EM et al. Quality of care for elderly patients hospitalized with heart failure. Arch. Intern. Med. 157(19), 2242–2247 (1997).
   PubMed Web of Science ®Google Scholar
• Phillips CO, Wright SM, Kern DE et al. Comprehensive discharge planning with postdischarge support for older patients with congestive heart failure: a meta-analysis. JAMA. 291(11), 1358–1367 (2004).
   PubMed Web of Science ®Google Scholar
• McAlister FA, Stewart S, Ferrua S et al. Multidisciplinary strategies for the management of heart failure patients at high risk for admission: a systematic review of randomized trials. J. Am. Coll. Cardiol. 44(4), 810–819 (2004).
   PubMed Web of Science ®Google Scholar